Literature DB >> 15280437

Haplotype-oriented genetic analysis and functional assessment of promoter variants in the MDR1 (ABCB1) gene.

Hiroshi Takane1, Daisuke Kobayashi, Takeshi Hirota, Junzo Kigawa, Naoki Terakawa, Kenji Otsubo, Ichiro Ieiri.   

Abstract

Recently, a number of nucleotide variants have been described in the multidrug resistance 1 (MDR1/ABCB1) gene; however, most studies have focused on the coding region. In the present study, we identified promoter variants of the MDR1 gene and evaluated their phenotypic consequences using a reporter gene assay and the real-time polymerase chain reaction method. Ten allelic variants were detected in the promoter region (approximately 2 kilobases), seven of which were newly identified. Certain mutations occurred simultaneously, and a total of 10 haplotypes were observed. These promoter polymorphisms were found more frequently in Japanese than Caucasians. Some haplotypes were associated with changes in luciferase activity and placental and hepatic mRNA levels. We also determined DNA methylation status in the proximal promoter region of the MDR1 gene. The promoter region around potential binding sites for transcription factors was found to be hypomethylated and thus likely to be independent of the gene expression. Nucleotide and/or haplotype variants not only in the coding region but also in the promoter region of the MDR1 gene may be important for interindividual differences of P-glycoprotein expression.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15280437     DOI: 10.1124/jpet.104.069724

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  19 in total

1.  Impact of CYP3A5 genetic polymorphism on pharmacokinetics of tacrolimus in healthy Japanese subjects.

Authors:  Yoshiharu Suzuki; Masato Homma; Kosuke Doki; Fumio Itagaki; Yukinao Kohda
Journal:  Br J Clin Pharmacol       Date:  2008-03-13       Impact factor: 4.335

2.  Influence of ABCB1 gene polymorphisms on the pharmacokinetics of verapamil among healthy Chinese Han ethnic subjects.

Authors:  Li-Mei Zhao; Xiao-Jing He; Feng Qiu; Ya-Xin Sun; Jesse Li-Ling
Journal:  Br J Clin Pharmacol       Date:  2009-09       Impact factor: 4.335

Review 3.  Search for genetic markers and functional variants involved in the development of opiate and cocaine addiction and treatment.

Authors:  Vadim Yuferov; Orna Levran; Dmitri Proudnikov; David A Nielsen; Mary Jeanne Kreek
Journal:  Ann N Y Acad Sci       Date:  2010-02       Impact factor: 5.691

Review 4.  Transporter-Mediated Disposition of Opioids: Implications for Clinical Drug Interactions.

Authors:  Robert Gharavi; William Hedrich; Hongbing Wang; Hazem E Hassan
Journal:  Pharm Res       Date:  2015-05-14       Impact factor: 4.200

5.  Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein).

Authors:  Laura M Hodges; Svetlana M Markova; Leslie W Chinn; Jason M Gow; Deanna L Kroetz; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2011-03       Impact factor: 2.089

6.  Differential effect of ABCB1 haplotypes on promoter activity.

Authors:  Jordan T Speidel; Meixiang Xu; Sherif Z Abdel-Rahman
Journal:  Pharmacogenet Genomics       Date:  2018-03       Impact factor: 2.089

7.  MGMT DNA repair gene promoter/enhancer haplotypes alter transcription factor binding and gene expression.

Authors:  Meixiang Xu; Courtney E Cross; Jordan T Speidel; Sherif Z Abdel-Rahman
Journal:  Cell Oncol (Dordr)       Date:  2016-06-15       Impact factor: 6.730

Review 8.  ATP-binding cassette efflux transporters in human placenta.

Authors:  Zhanglin Ni; Qingcheng Mao
Journal:  Curr Pharm Biotechnol       Date:  2011-04       Impact factor: 2.837

9.  MDR1 polymorphisms effect cyclosporine AUC0-4 values in Behçet's disease patients.

Authors:  Yoshihiko Katsuyama; Masao Ota; Nobuhisa Mizuki; Akiko Ito; Eiichi Okada; Shigeaki Ohno; Tamihide Matsunaga; Hirofumi Fukushima; Shigeru Ohmori
Journal:  Clin Ophthalmol       Date:  2007-09

10.  ABCB1 (MDR1) genetic variants are associated with methadone doses required for effective treatment of heroin dependence.

Authors:  Orna Levran; Kimberly O'Hara; Einat Peles; Dawei Li; Sandra Barral; Brenda Ray; Lisa Borg; Jurg Ott; Miriam Adelson; Mary Jeanne Kreek
Journal:  Hum Mol Genet       Date:  2008-04-17       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.